The Bayh-Dole Act (Patent and Trademark Law Amendments Act) for the first time allowed universities which held patents obtained as a result of Government Funded Research to enter into agreements with corporations to develop new drugs from those patents. The theory was that, the number of new drugs brought to the market would substantially increase beyond only the hundred or so that appeared each year. Unfortunately, the legislation did not have the desired effect. By the first decade of the 21st century, the number of annual NEW drugs being brought to market was under 30 and in 2010 was only 10. The cost of going through required trials for FDA drug approval has reached hundreds of millions of dollars, and most organizations cannot afford to even make the attempt. Even if a drug is very promising, the drug companies will not invest the money unless there are enough people suffering from the malady the drug treats and the medicine has to be taken for a long time as with chronic conditions. The system works poorly for the society and the health system. Reforms are needed.